Cholera in the 21st century

Current Opinion in Infectious Diseases

Volumn 24, Issue 5, 2011, Pages 472-477

  Charles, Richelle C ^a,b   Ryan, Edward T ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cholera; diarrhea; outbreak; vaccine; Vibrio cholerae

Indexed keywords

ANTIINFECTIVE AGENT; CHOLERA TOXIN; CHOLERA VACCINE; HOST FACTOR; LIVE VACCINE; SHANCHOL; UNCLASSIFIED DRUG;

CHOLERA; DEHYDRATION; DISEASE TRANSMISSION; ENVIRONMENTAL SANITATION; EPIDEMIC; HOST PATHOGEN INTERACTION; HUMAN; IMMUNITY; INFECTION SENSITIVITY; MORTALITY; NONHUMAN; REHYDRATION; REVIEW; VIBRIO CHOLERAE;

CHOLERA; CHOLERA VACCINES; DISEASE OUTBREAKS; HUMANS; SANITATION; VACCINATION; VIBRIO CHOLERAE;

EID: 80052460724     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834a88af     Document Type: Review

References (61)

1. Cholera vaccines:WHOposition paper. Wkly Epidemiol Rec 2010; 85:117-128.
2. Harris JB, Larocque RC, Charles RC, et al. Cholera's western front. Lancet 2010; 376:1961-1965.
3. PAHO. Health cluster bulletin #24: cholera and post-earthquake response in Haiti. 2011. Available at: http:new.paho.org/blogs/haiti/?p1972. [Accessed 20 May 2011]
4. WHO. The seventh cholera pandemic. WHO Chron 1971; 25:155-160.
5. Pradhan S, Baidya AK, Ghosh A, et al. The El Tor biotype of Vibrio cholerae exhibits a growth advantage in the stationary phase in mixed cultures with the classical biotype. J Bacteriol 2010; 192:955-963.
6. Safa A, Nair GB, Kong RY. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 2010; 18:46-54.
7. Ghosh-Banerjee J, Senoh M, Takahashi T, et al. Cholera toxin production by the El Tor variant of Vibrio cholerae O1 compared to prototype El Tor and classical biotypes. J Clin Microbiol 2010; 48:4283-4286.
8. Garriss G, Waldor MK, Burrus V. Mobile antibiotic resistance encoding elements promote their own diversity. PLoS Genet 2009; 5:e1000775.
9. Islam MS, Mahmud ZH, Ansaruzzaman M, et al. Phenotypic, genotypic and antibiotic sensitivity patterns of strains isolated from the cholera epidemic in Zimbabwe. J Clin Microbiol 2011; 49:2325-2327.
10. Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354:2452-2462. (Pubitemid 43855048)
11. Kim HB, Wang M, Ahmed S, et al. Transferable quinolone resistance in Vibrio cholerae. Antimicrob Agents Chemother 2010; 54:799-803.
12. Pan JC, Ye R, Wang HQ, et al. Vibrio cholerae O139 multiple-drug resistance mediated by Yersinia pestis pIP1202-like conjugative plasmids. Antimicrob Agents Chemother 2008; 52:3829-3836.
13. Chin CS, Sorenson J, Harris JB, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 2011; 364:33-42.
14. Centers for DiseaseControl and Prevention(CDC).Update: cholera outbreak-Haiti, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1473-1479.
15. Ali A, Chen Y, Johnson JA, et al. Recent clonal origin of cholera in Haiti. Emerg Infect Dis 2011; 17:699-701.
16. Cravioto A, Lanata CF, Lantagne DS, Nair GB. Final report of the independent panel of experts on the cholera outbreak in Haiti. 2011. Available at: http://www.un.org/News/dh/infocus/haiti/UN-cholera-report-final.pdf. [Accessed 23. May 2011]
17. Constantin de Magny G, Murtugudde R, Sapiano MR, et al. Environmental signatures associated with cholera epidemics. Proc Natl Acad Sci USA 2008; 105:17676-17681.
18. Reyburn R, Kim DR, Emch M, et al. Climate variability and the outbreaks of cholera in Zanzibar, east Africa: a time series analysis. Am J Trop Med Hyg 2011; 84:862-869.
19. Harris AM, Chowdhury F, Begum YA, et al. Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. Am J Trop Med Hyg 2008; 79:708-714.
20. Faruque SM, Naser IB, Islam MJ, et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Natl Acad Sci USA 2005; 102:1702-1707. (Pubitemid 40209231)
21. Faruque SM, Islam MJ, Ahmad QS, et al. Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phage. Proc Natl Acad Sci USA 2005; 102:6119-6124. (Pubitemid 40594265)
22. Zahid MS, Udden SM, Faruque AS, et al. Effect of phage on the infectivity of Vibrio cholerae and emergence of genetic variants. Infect Immun 2008; 76:5266-5273.
23. Nelson EJ, Chowdhury A, Harris JB, et al. Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea. Proc Natl Acad Sci USA 2007; 104:19091-19096.
24. Alam M, Sultana M, Nair GB, et al. Toxigenic Vibrio cholerae in the aquatic environment of Mathbaria, Bangladesh. Appl Environ Microbiol 2006; 72:2849-2855.
25. Nelson EJ, Chowdhury A, Flynn J, et al. Transmission of Vibrio cholerae is antagonized by lytic phage and entry into the aquatic environment. PLoS Pathog 2008; 4:e1000187.
26. Faruque SM, Biswas K, Udden SM, et al. Transmissibility of cholera: in vivoformed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci USA 2006; 103:6350-6355.
27. Harris JB, Larocque RC, Chowdhury F, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2008; 2:e221.
28. Weil AA, Khan AI, Chowdhury F, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis 2009; 49:1473-1479.
29. Merrell DS, Butler SM, Qadri F, et al. Host-induced epidemic spread of the cholera bacterium. Nature 2002; 417:642-645. (Pubitemid 34614821)
30. Alam A, Larocque RC, Harris JB, et al. Hyperinfectivity of human-passaged Vibrio cholerae can be modeled by growth in the infant mouse. Infect Immun 2005; 73:6674-6679. (Pubitemid 41368833)
31. Hartley DM, Morris JG Jr, Smith DL. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS Med 2006; 3:e7.
32. Butler SM, Nelson EJ, Chowdhury N, et al. Cholera stool bacteria repress chemotaxis to increase infectivity. Mol Microbiol 2006; 60:417-426.
33. Angelichio MJ, Merrell DS, Camilli A. Spatiotemporal analysis of acid adaptation-mediated Vibrio cholerae hyperinfectivity. Infect Immun 2004; 72:2405-2407. (Pubitemid 38419960)
34. Nielsen AT, Dolganov NA, Rasmussen T, et al. A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathog 2010; 6:e1001102.
35. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005; 73:7422-7427. (Pubitemid 41587645)
36. Rahman KM, Duggal P, Harris JB, et al. Familial aggregation of Vibrio cholerae-associated infection in Matlab, Bangladesh. J Health Popul Nutr 2009; 27:733-738.
37. Larocque RC, Sabeti P, Duggal P, et al. A variant in long palate, lung and nasal epithelium clone 1 is associated with cholera in a Bangladeshi population. Genes Immun 2009; 10:267-272.
38. Harris JB, Podolsky MJ, Bhuiyan TR, et al. Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl Trop Dis 2009; 3:e403.
39. Koelle K, Rodo X, Pascual M, et al. Refractory periods and climate forcing in cholera dynamics. Nature 2005; 436:696-700. (Pubitemid 41117271)
40. Saha D, LaRocque RC, Khan AI, et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 2004; 189:2318-2322. (Pubitemid 38757206)
41. Harris AM, Bhuiyan MS, Chowdhury F, et al. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 2009; 77:3850-3856.
42. Uddin T, Harris JB, Bhuiyan TR, et al. Mucosal immunologic responses in cholera patients in Bangladesh. Clin Vaccine Immunol 2011; 18:506-512.
43. Weil AA, Arifuzzaman M, Bhuiyan TR, et al. Memory T cell responses to Vibrio cholerae O1 infection. Infect Immun 2009; 77:5090-5096.
44. Alam MM, Riyadh MA, Fatema K, et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one or two dose oral killed cholera vaccination, and comparison with responses following natural cholera. Clin Vaccine Immunol 2011; 18:844-850.
45. Chowdhury F, Khan AI, Faruque AS, Ryan ET. Severe, acute watery diarrhea in an adult. PLoS Negl Trop Dis 2010; 4:e898.
46. Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967; 36:871-883.
47. Farmer P, Almazor CP, Bahnsen ET, et al. Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis 2011; 5:e1145.
48. Andrews JR, Basu S. Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet 2011; 377:1248-1255.
49. WHO/UNICEF. Status and progress towards the MDG target. In: Progress on sanitation and drinking water: 2010 update. Switzerland: WHO Press; 2010. pp. 6-13
50. Ryan ET. The cholera pandemic, still with us after half a century: time to rethink. PLoS Negl Trop Dis 2011; 5:e1003.
51. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2:467-470.
52. Chowdhury MI, Sheikh A, Qadri F. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Expert Rev Vaccines 2009; 8:1643-1652.
53. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270-273. (Pubitemid 20047723)
54. Clemens JD, Harris JR, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 1988; 158:60-69.
55. Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killedwhole-cell oral cholera vaccine in India: an interim analysis of a clusterrandomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1694-1702.
56. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44-49. (Pubitemid 40956529)
57. Reyburn R, Deen JL, Grais RF, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis 2011; 5:e952.
58. Miller Neilan RL, Schaefer E, Gaff H, et al. Modeling optimal intervention strategies for cholera. Bull Math Biol 2010; 72:2004-2018.
59. Chao DL, Halloran ME, Longini IM Jr. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci USA 2011; 108:7081-7085.
60. Anh DD, Lopez AL, Thiem VD, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011; 5:e1006.
61. Tuite AR, Tien J, Eisenberg M, et al. Cholera epidemic in Haiti, 2010: using a transmission model to explain spatial spread of disease and identify optimal control interventions. Ann Intern Med 2011; 154:593-601.